Can I read Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety on EtoBox?
Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety by Correia, Eduardo Thadeu de Oliveira; dos Santos Barbetta, Letícia Mara; de Almeida, João Paulo Chevrand Latini; Mesquita, Evandro Tinoco is a Medicine article available to read on EtoBox.
What is Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety about?
Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
Who reads Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Correia, Eduardo Thadeu de Oliveira; dos Santos Barbetta, Letícia Mara; de Almeida, João Paulo Chevrand Latini; Mesquita, Evandro Tinoco
- Publisher
- Lippincott Williams and Wilkins; Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins; Lippincott Williams & Wilkins Ltd.; Ovid Technologies (Wolters Kluwer Health) (ISSN 0160-2446)
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)